Piper Jaffray Companies reiterated their hold rating on shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in a report issued on Friday. Piper Jaffray Companies currently has a $1.50 price target on the medical device company’s stock.
Separately, Zacks Investment Research upgraded shares of Tandem Diabetes Care from a hold rating to a buy rating and set a $0.75 target price on the stock in a research note on Thursday, September 28th. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of Buy and a consensus target price of $4.09.
Shares of Tandem Diabetes Care (TNDM) opened at 5.811 on Friday. Tandem Diabetes Care has a 1-year low of $0.39 and a 1-year high of $7.89. The firm’s market capitalization is $291.87 million. The firm has a 50-day moving average price of $0.68 and a 200-day moving average price of $0.79.
Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Thursday, July 27th. The medical device company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.04. The company had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $21.74 million. Tandem Diabetes Care had a negative net margin of 110.70% and a negative return on equity of 1,177.11%. The firm’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.60) EPS. On average, analysts forecast that Tandem Diabetes Care will post ($1.79) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/tandem-diabetes-care-inc-tndm-earns-hold-rating-from-piper-jaffray-companies/1703202.html.
Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Tandem Diabetes Care by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock valued at $987,000 after purchasing an additional 32,991 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Tandem Diabetes Care by 88.6% in the 1st quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock valued at $1,032,000 after purchasing an additional 404,452 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Tandem Diabetes Care by 93.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock valued at $465,000 after purchasing an additional 280,551 shares in the last quarter. Paulson & CO. Inc. acquired a new stake in shares of Tandem Diabetes Care in the 1st quarter valued at about $600,000. Finally, Keybank National Association OH raised its stake in shares of Tandem Diabetes Care by 32.7% in the 2nd quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock valued at $235,000 after purchasing an additional 72,177 shares in the last quarter. Institutional investors and hedge funds own 36.64% of the company’s stock.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with our FREE daily email newsletter.